Image: The Pharmaceutical JournalA faster route to rare disease treatments: the MHRA’s proposals - The Pharmaceutical Journal
• The Medicines and Healthcare products Regulatory Agency (MHRA) is proposing a shake-up of the UK's medicines approval process to accelerate the development of treatments for rare diseases. • With approximately 10,000 rare diseases existing, the vast majority currently lack effective therapies, creating significant gaps in patient care. • The economic impact is severe, with the MHRA estimating that delayed diagnoses cost £340 million annually and health-related disability costs reach £4.7 billion.
pharmaceutical-journal.com

